Pancreatic cancer ‘mismatch’ in Lynch syndrome

OBJECTIVE: Immune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable/metastatic solid tumours exhibiting mismatch repair (MMR) deficiency. Lynch syndrome (LS), caused by autosomal dominant germline mutations of a MMR gene, predisposes to the development of MMR-defic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMJ Open Gastroenterol
Main Authors: Hendifar, Andrew E, Larson, Brent K, Rojansky, Rebecca, Guan, Michelle, Gong, Jun, Placencio, Veronica, Tuli, Richard, Hitchins, Megan
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6577306/
https://ncbi.nlm.nih.gov/pubmed/31275582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2019-000274
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki